FeesSafety
Pluang+

Atebimetinib shows promise for treating aggressive anaplastic thyroid cancer, expanding Immuneering's cancer drug pipeline.

Market News
18 Nov 2026, 14:30 WIB
GlobeNewsWire
View Source
Bullish
Atebimetinib shows promise for treating aggressive anaplastic thyroid cancer, expanding Immuneering's cancer drug pipeline.

Immuneering Corporation announced new preclinical data supporting the expansion of its drug atebimetinib to treat anaplastic thyroid cancer (ATC), a highly aggressive cancer with limited options. Atebimetinib showed broad anti-tumor activity across diverse ATC cell lines and improved tumor control when combined with chemotherapy in animal models, outperforming existing therapies. This supports Immuneering's planned Phase 2 clinical trial for ATC patients, including those resistant to current targeted treatments. The development marks a significant step in addressing the urgent need for better ATC therapies and complements ongoing trials in pancreatic and lung cancers.

Immuneering's new data on expanding atebimetinib for anaplastic thyroid cancer provides context for healthcare sector activity. For readers following this sector, here is Pluang's market snapshot as of Nov 18, 2026 19:21 WIB: Among 150 priced health-sector US stocks, 55 rose and 86 fell today. Notable moves include BKD at USD 8.60 with a -2.27% change and a typical hold time of 9 days, FLNA at USD 0.47 down -2.22% with 97% sell order activity and a 39-day hold, and TNGX at USD 22.60 up 2.22% with a 5-day hold time.

More News

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
42 minutes ago
Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgraded Charles Schwab to Strong Buy following strong growth in October 2026. Client assets rose 12% year over year to $13.27 trillion, with core net new assets surging 50% to $66.5 billion, a record for the month. Schwab also opened 4...

Analyst Insights
Bullish
1 hour ago
SDVerse named CES Innovation Awards 2027 Honoree for AI-powered automotive software marketplace.

SDVerse named CES Innovation Awards 2027 Honoree for AI-powered automotive software marketplace.

SDVerse, a B2B automotive software marketplace founded by General Motors, Magna, and Wipro, was honored with a CES Innovation Award 2027 in the Enterprise Tech category. The platform uses AI and standardized technical data to help automakers and supp...

Others
Bullish
1 hour ago
Progressive Ventures closes $12.24M fund to back early-stage B2B AI startups before Demo Days.

Progressive Ventures closes $12.24M fund to back early-stage B2B AI startups before Demo Days.

Progressive Ventures, a Silicon Valley venture firm, has closed its first fund at $12.24 million to invest in early-stage B2B AI and SaaS startups from programs like Y Combinator and Berkeley SkyDeck before their Demo Days. The fund has already backe...

Others
Bullish
1 hour ago
Virbac to present at Jefferies Global Healthcare Conference in London on Nov 18, 2026

Virbac to present at Jefferies Global Healthcare Conference in London on Nov 18, 2026

Virbac announced that CEO Paul Martingell and CFO Habib Ramdani will present and hold a Q&A session at the Jefferies Global Healthcare Conference in London on November 18, 2026. Investors and interested parties can watch the live webcast on Virbac's ...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App